600535.SS Stock Analysis
60
Neutral
Based on Eyestock quantitative analysis, 600535.SS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Moderate score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Market cap $B
3.049
Dividend yield
3.74 %
Shares outstanding
1 493.95 B
Website
https://www.taslypharma.com/Tasly Pharmaceutical Group Co., Ltd. engages in the development, manufacture and distribution of pharmaceutical products. The company is headquartered in Tianjin, Tianjin and currently employs 9,437 full-time employees. The company went IPO on 2002-08-23. The firm's main businesses include the manufacture and sales of traditional Chinese medicines, chemical preparations, chemical raw materials and biological medicines. The firm's main products include Compound Danshen Dropping Pills, Yangxuenao Granules, Yangxuenao Pills, Qishen Yiqi Dropping Pills, Diqing and Shuilinjia. Its products are used to treat cardiovascular and cerebrovascular diseases, tumors, colds, fevers and liver diseases. The firm mainly distributes its products in the domestic market.